Browsing Tag
BIO International Convention
3 posts
Why Avacta’s (AVCT) smallest FAP signal could create a much bigger opportunity for pre|CISION
Avacta Group’s latest faridoxorubicin findings suggest pre|CISION may activate effectively even in tumours with minimal FAP expression, potentially widening the platform’s commercial reach while raising the importance of mature progression-free survival data and a development partnership.
Avacta just won a clean FDA path to full AVA6000 approval, so why did $AVCT barely move?
Avacta won a clean FDA path to full AVA6000 approval, yet AVCT (AIM) barely moved. The real question is whether a partner signs before cash runs low.
Avacta targets late-2026 AVA6103 data as AVCT shifts from funding risk to clinical proof
Avacta Group has outlined a catalyst-heavy second half of 2026, with new AVA6000 data, the first AVA6103 clinical results and potential partnering decisions set to test the commercial value of its tumour-activated oncology platform.